| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| - | - | 520 | ₹0.1 -50% | 43,0002.38% |
| 1,0000% | ₹70.35 0% | 540 | ₹0.1 -50% | 28,000-12.5% |
| 3,0000% | ₹76.1 0% | 550 | ₹0.1 100% | 1,49,0000% |
| 21,0000% | ₹79 0% | 560 | ₹0.2 33.33% | 1,53,000-3.77% |
| 11,0000% | ₹73.25 0% | 570 | ₹0.4 14.28% | 74,0000% |
| 17,0000% | ₹51.8 0% | 580 | ₹0.5 0% | 1,99,000-23.75% |
| 26,0000% | ₹56.3 0% | 590 | ₹0.85 30.76% | 1,31,00012.93% |
| 1,19,000-0.83% | ₹32.9 -31.24% | 600 | ₹1.65 32% | 5,85,000-1.34% |
| 78,000-10.34% | ₹23.15 -41.01% | 610 | ₹3.15 57.5% | 2,16,0005.36% |
| 3,09,0005.10% | ₹16.6 -37.35% | 620 | ₹5.75 66.66% | 4,23,0001.43% |
| 5,05,00013.73% | ₹10.8 -44.32% | 630 | ₹10 61.29% | 4,06,000-5.14% |
| 7,09,00027.74% | ₹7.05 -47.77% | 640 | ₹15.8 57.21% | 3,48,000-7.44% |
| 11,79,000-1.58% | ₹4.6 -50.27% | 650 | ₹24.5 54.57% | 3,00,000-9.09% |
| 9,94,0008.75% | ₹3.25 -49.21% | 660 | ₹33.1 41.75% | 1,24,0005.08% |
| 9,86,00012.68% | ₹2.2 -51.64% | 670 | ₹41.7 36.72% | 92,000-2.12% |
| 10,45,00016.75% | ₹1.4 -55.55% | 680 | ₹50.1 24.47% | 1,76,000-2.76% |
| 7,32,000-30.28% | ₹1.1 -54.16% | 690 | ₹61.15 -11.31% | 23,000-8% |
| 39,69,00014.84% | ₹0.9 -50% | 700 | ₹61.05 4.8% | 2,29,0000% |
| 4,04,000-7.33% | ₹0.65 -43.47% | 710 | ₹73.9 0% | 21,0000% |
| 13,62,00024.27% | ₹0.65 -35% | 720 | ₹75.75 0% | 63,0000% |
| 3,39,000-2.58% | ₹0.45 -47.05% | 730 | ₹90 9.02% | 13,000-18.75% |
| 2,64,000-8.96% | ₹0.5 -37.5% | 740 | ₹100 6.38% | 23,0000% |
| 7,90,000-5.04% | ₹0.45 -18.18% | 750 | ₹110.05 2.85% | 1,13,0000% |
| 3,35,000-14.54% | ₹0.35 -36.36% | 760 | - | - |
| 16,000-51.51% | ₹0.25 -16.66% | 770 | - | - |
| 1,44,000-7.09% | ₹0.3 0% | 780 | ₹105 0% | 2,0000% |
| 53,0000% | ₹0.4 0% | 790 | - | - |
| 8,32,000-17.86% | ₹0.3 0% | 800 | ₹193.25 0% | 39,0000% |
| 4,0000% | ₹0.2 -76.47% | 810 | - | - |
| 6,91,000-13.84% | ₹0.25 0% | 820 | - | - |
| 1,24,000-4.61% | ₹0.1 -60% | 840 | ₹199.25 0.05% | 5,0000% |
The purchase is anticipated to enhance Syngene's position in the biologics contract development and manufacturing organization (CDMO) arena, specifically in the US market.
The company reported an operating EBITDA of ₹343.60 Crore in the quarter four of FY25. It registered a growth of 8.4% on a year-on-year basis.
This acquisition will also augment Syngene’s biologics capabilities and further strengthen its global presence.
The company's revenue from operations also grew healthily, up by 10.6% YoY to ₹943 crore, as against ₹853.5 crore in Q3 FY24.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
